The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

February 1, 2020

Study Completion Date

February 1, 2020

Conditions
Cardiovascular DiseasesCardiovascular Risk FactorVasoconstriction
Interventions
DRUG

Control (Phenylephrine)

This intervention is aimed at assessing the vascular responsiveness to phenylephrine, an alpha 1-agonist, in white and black men and women across a series of ascending dose concentrations.

DRUG

Phenylephrine + Apocynin

This intervention is meant to assess the impact of NADPH oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme NADPH oxidase.

DRUG

Phenylephrine + Allopurinol

This intervention is meant to assess the impact of xanthine oxidase-derived superoxide on vasoconstrictor responses by inhibiting the enzyme xanthine oxidase.

DRUG

Phenylephrine + Tempol

This intervention is meant to assess the impact of superoxide on vasoconstrictor responses by scavenging available superoxide.

Trial Locations (1)

76019

Science and Engineering Research and Innovation Building, Arlington

All Listed Sponsors
lead

The University of Texas at Arlington

OTHER

NCT03680404 - The Effect of Local Antioxidant Therapy on Racial Differences in Vasoconstriction | Biotech Hunter | Biotech Hunter